ThormannASorensenPSKoch-HenriksenN, et al. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology2017; 89: 1668–1675.
2.
ZhangTTremlettHLeungS, et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology2016; 86: 1287–1295.
3.
ConwayDSThompsonNRCohenJA.Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course. Mult Scler2017; 23(2): 277–285.
4.
GrahamG.Disparities in cardiovascular disease risk in the United States. Curr Cardiol Rev2015; 11: 238–245.
5.
Gómez-FigueroaEde SaráchagaAJGarcía-EstradaC, et al. Socioeconomic status and access to multiple sclerosis treatment in Mexico. Mult Scler Relat Disord2021; 52: 102967.
6.
RobersMChanCVajdiB, et al. Hypertension and hypertension severity in Hispanics/LatinX with MS. Mult Scler J2021; 27(12): 1894–1901.
7.
RotsteinDMaxwellCTuK, et al. High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis. Mult Scler J2021; 27(12) 1902–1913.
8.
LewisVAFrazeTFisherES, et al. ACOs serving high proportions of racial and ethnic minorities lag in quality performance. Health Aff2017; 36: 57–66.
9.
NgESanmartinCManuelDG.Hospitalization rates among economic immigrants to Canada. Health Rep2014; 28: 3–10.
10.
RotsteinDLMarrieRATuK, et al. Health service utilization in immigrants with multiple sclerosis. PLoS ONE2020; 15(7): e0234876.
